Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efpeglenatide - Sanofi

Drug Profile

Efpeglenatide - Sanofi

Alternative Names: HM-11260C; Langlenatide; LAPS-Exd4; LAPS-Exendin; LAPS-exendin 4 analogue; LAPS-Exendin4; LAPSCA-Exendin4; SAR-439977

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Sanofi
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Obesity therapies; Peptides; Polyethylene glycols; Pyrrolidines
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 20 Aug 2019 Sanofi initiates enrolment in a phase III trial for Type 2 diabetes mellitus (Treatment-experienced) in USA (NCT03713684)
  • 15 Aug 2019 Sanofi initiates enrolment in phase III AMPLITUDE-S trial for Type 2 diabetes mellitus (Adjunctive therapy) in USA (SC) (NCT03770728)
  • 07 Jun 2019 Subgroup analysis efficacy data from the phase IIb trial in Obesity presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top